{"nctId":"NCT00603798","briefTitle":"Safety and Effectiveness Study of Imiquimod Creams for the Treatment of Actinic Keratoses (AKs)","startDateStruct":{"date":"2008-01"},"conditions":["Actinic Keratosis"],"count":490,"armGroups":[{"label":"3.75% imiquimod cream","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: Imiquimod cream"]},{"label":"2.5% imiquimod cream","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: Imiquimod cream"]},{"label":"Placebo cream","type":"PLACEBO_COMPARATOR","interventionNames":["Drug: Placebo cream"]}],"interventions":[{"name":"Imiquimod cream","otherNames":[]},{"name":"Placebo cream","otherNames":[]},{"name":"Imiquimod cream","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* In good general health.\n* Have 5 to 20 AKs on the face or balding scalp.\n* Negative pregnancy test (for women who are able to become pregnant).\n* Willing to make frequent visits to the study center during the treatment and follow-up periods.\n\nExclusion Criteria:\n\n* Women who are pregnant, lactating or planning to become pregnant during the study.\n* Have had a medical event within 90 days of the first visit (such as: stroke, heart attack).\n* Have any skin condition in the treatment area that may be made worse by treatment with imiquimod (such as: rosacea, psoriasis, atopic dermatitis, eczema).\n* Have received specific treatments/medications in the treatment area(s) within the designated time period prior to study treatment initiation.","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Number of Participants With Complete Clearance of AK Lesions","description":"Subject status with respect to complete clearance of AK lesions at End of Study (EOS), ie, the Week 17 visit. Complete clearance was defined as the absence of clinically visible or palpable AK lesions in the treatment area. All lesions within the identified treatment area were included in the count, even if the lesion was a new lesion or \"subclinical\" lesion that had not been identified at Baseline.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"55","spread":null},{"groupId":"OG001","value":"41","spread":null},{"groupId":"OG002","value":"9","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Participants With Partial Clearance of AK Lesions","description":"Subject status with respect to complete clearance of AK lesions at End of Study (EOS), defined as at least a 75% reduction in the number of AK lesions in the treatment area compared with Baseline.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"87","spread":null},{"groupId":"OG001","value":"70","spread":null},{"groupId":"OG002","value":"21","spread":null}]}]}]},{"type":"SECONDARY","title":"Percent Change From Baseline in AK Lesion Count","description":"Percent change from Baseline to end of study (EOS) in investigator counts of AK lesions. A negative percent change is better than a positive percent change.","paramType":"MEDIAN","dispersionType":"Full Range","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-80.0","spread":null},{"groupId":"OG001","value":"-66.7","spread":null},{"groupId":"OG002","value":"-23.6","spread":null}]}]}]},{"type":"SECONDARY","title":"Local Skin Reactions (LSR)","description":"Six local skin reaction (LSR) signs were predefined and were assessed for presence and intensity at each visit. These included: Erythema, edema, Weeping/Exudate, Flaking/Scaling/Dryness, Scabbing/Crusting and Erosion/Ulceration. The LSRs were scored as 0=none, 1=mild, 2=moderate, 3=severe. Summary of LSR - area under the curve (AUC) of sum of LSR scores (days).","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"413.5","spread":"187.7"},{"groupId":"OG001","value":"372.0","spread":"180.6"},{"groupId":"OG002","value":"188.6","spread":"136.7"}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":10,"n":162},"commonTop":["Application site pruritus","Application site pain","Application site irritation"]}}}